Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akorn, Inc. stock logo
AKRX
Akorn
$0.19
$0.09
$5.46
$3.60M0.959.60 million shs1.19 million shs
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
$0.07
$0.08
$0.06
$1.31
$727K1.3922,874 shs6,059 shs
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$2.60
-1.1%
$3.04
$1.94
$14.00
$3.92M0.04124,695 shs15,610 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$2.52
+0.8%
$5.84
$2.43
$110.75
$2.55M0.6953,614 shs63,522 shs
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
$0.00
$0.00
$0.00
$0.07
N/A3.0317 shs13 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akorn, Inc. stock logo
AKRX
Akorn
0.00%0.00%0.00%0.00%0.00%
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
0.00%-2.05%-21.63%-4.36%-58.57%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.00%-10.71%-42.00%-47.48%-97.21%
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
0.00%0.00%0.00%-85.71%-85.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/AN/AN/AN/A
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
1.1863 of 5 stars
0.05.00.00.02.90.00.6
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
2.0545 of 5 stars
3.53.00.00.01.80.00.6
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akorn, Inc. stock logo
AKRX
Akorn
0.00
N/AN/AN/A
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
0.00
N/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
0.00
N/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
3.00
Buy$60.002,280.95% Upside
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EVOK, AKRX, BLCM, JAGX, and RGRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
First Berlin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akorn, Inc. stock logo
AKRX
Akorn
$682.43M0.00N/A0.19$1.86 per share0.00
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
$1.50M0.48N/AN/A$0.23 per share0.33
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$10.25M0.38N/AN/A$4.74 per share0.55
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$11.69M0.22N/AN/A$12.29 per share0.21
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
$80K0.00N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akorn, Inc. stock logo
AKRX
Akorn
-$226.77M-$0.34N/AN/AN/A-55.64%8.53%1.31%N/A
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
-$24.97MN/A0.00N/AN/AN/A-157.93%N/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$5.35M-$2.87N/AN/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
-$1.73MN/A0.00N/AN/AN/AN/AN/A

Latest EVOK, AKRX, BLCM, JAGX, and RGRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million
5/12/2025Q1 2025
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/A
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
N/AN/AN/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
N/AN/AN/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akorn, Inc. stock logo
AKRX
Akorn
0.09
0.50
0.32
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
N/A
3.04
3.04
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
1.55
1.50
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
22.20
1.08
0.70
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Akorn, Inc. stock logo
AKRX
Akorn
64.03%
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
4.93%
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
12.04%
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Akorn, Inc. stock logo
AKRX
Akorn
2,227133.15 millionN/AOptionable
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
139.72 million8.72 millionNot Optionable
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
41.49 million1.40 millionNot Optionable
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
501.02 million1.01 millionNo Data
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
31.51 million1.32 millionNot Optionable

Recent News About These Companies

EIGRQ Eiger BioPharmaceuticals, Inc.
The Hawryluk Biopharmaceutical Scholars
Regenerx Biopharmaceuticals Inc RGRXD
Regenerx Biopharm In (RGRXD)
RGRX RegeneRx Biopharmaceuticals, Inc.
RegeneRx To Extend Consent Solicitation Vote
Bristol-Myers to Split Off Mead Johnson

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akorn stock logo

Akorn NASDAQ:AKRX

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Bellicum Pharmaceuticals stock logo

Bellicum Pharmaceuticals NASDAQ:BLCM

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Evoke Pharma stock logo

Evoke Pharma NASDAQ:EVOK

$2.60 -0.03 (-1.14%)
As of 03:59 PM Eastern

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Jaguar Animal Health stock logo

Jaguar Animal Health NASDAQ:JAGX

$2.52 +0.02 (+0.80%)
As of 04:00 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

RegeneRx Biopharmaceuticals stock logo

RegeneRx Biopharmaceuticals OTCMKTS:RGRX

$0.0002 0.00 (0.00%)
As of 06/27/2025

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.